AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 11.01 |
Market Cap | 2.61B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.5 |
PE Ratio (ttm) | -18.37 |
Forward PE | n/a |
Analyst | Buy |
Ask | 29.98 |
Volume | 1,744,737 |
Avg. Volume (20D) | 800,331 |
Open | 25.75 |
Previous Close | 25.33 |
Day's Range | 24.95 - 27.87 |
52-Week Range | 9.00 - 38.12 |
Beta | undefined |
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that t...
Analyst Forecast
According to 6 analyst ratings, the average rating for EWTX stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 81.49% from the latest price.
2 weeks ago · seekingalpha.com
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy DataCompany achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON st...